| With IVPG of ≥ 30 mmHg (n = 30) | Without IVPG of ≥ 30 mmHg (n = 30) | P-value |
---|---|---|---|
Age (years) | 56 ± 13 | 54 ± 18 | 0.55 |
Male | 20 (67%) | 22 (73%) | 0.78 |
NYHA functional class I/II/III | 14/13/3 | 17/13/0 | 0.19 |
NSVT | 26 (87%) | 22 (73%) | 0.33 |
Unexplained syncope | 11 (37%) | 14 (47%) | 0.60 |
Family history of sudden death | 10 (33%) | 9 (30%) | 1.00 |
Abnormal BP response during exercise | 6 (20%) | 7 (23%) | 1.00 |
Maximum LV wall thickness ≥ 30 mm | 4 (13%) | 3 (10%) | 1.00 |
Number of major conventional risk factors | Â | Â | 0.21 |
1 | 12 (40%) | 10 (33%) | Â |
2 | 9 (30%) | 16 (53%) | Â |
3 | 8 (27%) | 4 (13%) | Â |
4 | 1 (3%) | 0 | Â |
HCM risk-SCD score | |||
5-year risk (%) | 5.3 (3.1–8.1) | 4.0 (3.0–5.9) | 0.14 |
Category* | Â | Â | 0.38 |
High risk | 12 (40%) | 6 (20%) | Â |
Intermediate risk | 7 (23%) | 9 (30%) | Â |
Low risk | 11 (37%) | 15 (50%) | Â |
Cardiac magnetic resonance imaging | (n = 23) | (n = 17) |  |
LGE-positive | 19 (83%) | 15 (88%) | 1.00 |
LV mass (g) | 112 ± 44 | 107 ± 44 | 0.72 |
Electrophysiological study | (n = 15) | (n = 23) |  |
Inducible VT or VF | 8 (53%) | 6 (26%) | 0.49 |
Portion of LV obstruction | |||
Outflow tract | 18 (60%) | Â | Â |
Mid-ventricle | 12 (40%) | Â | Â |
Echocardiographic parameters | |||
Left atrial dimension (mm) | 37 ± 6 | 41 ± 9 | 0.10 |
LV end-diastolic dimension (mm) | 43 ± 7 | 46 ± 7 | 0.19 |
LV end-systolic dimension (mm) | 27 ± 7 | 29 ± 6 | 0.28 |
LV ejection fraction (%) | 61 ± 11 | 62 ± 10 | 0.84 |
Maximum LV wall thickness (mm) | 21 ± 7 | 19 ± 7 | 0.20 |
Implantable cardioverter defibrillator | |||
Subcutaneous type | 0 | 1 (3%) | Â |
Transvenous type | 30 (100%) | 29 (97%) | Â |
 Pacing mode |  |  |  |
  AAI | 0 | 1 (3%) |  |
  VVI | 3 (10%) | 10 (35%) |  |
  DDI | 3 (10%) | 1 (3%) |  |
  DDD | 24 (80%) | 17 (59%) |  |
 RV pacing > 95% | 17 (57%) | 2 (7%) |  < 0.01 |
Tachycardia detection setting/therapy setting | |||
 VF zone | 30/30 | 30/30 |  |
 Fast VT zone | 7/7 | 11/11 |  |
 VT zone | 25/13 | 24/5 |  |
Medications | |||
Beta-blockers | 27 (90%) | 26 (87%) | 1.00 |
Calcium channel blockers | 5 (17%) | 4 (13%) | 1.00 |
ACE inhibitors/ARBs | 7 (23%) | 19 (63%) |  < 0.01 |
Class I antiarrhythmic drugs | 11 (37%) | 1 (3%) |  < 0.01 |
Amiodarone | 8 (27%) | 8 (27%) | 1.00 |